- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 23.10. | Pfizer gets a leg up in RSV as FDA clears jab for all adults | ||
| 23.10. | Lawmakers seek answers on Pfizer, Lilly telehealth moves | ||
| 23.10. | UK 'should abolish clock changes on health grounds' | ||
| 23.10. | Starboard spells out its concerns with Pfizer's direction | ||
| 22.10. | Otsuka eyes early filing of IgAN drug after phase 3 readout | ||
| 22.10. | Europe's share of clinical trials falling, with China rising | ||
| 22.10. | France warns of penalties if Opella production goes offshore | ||
| 22.10. | AZ, Ionis get CHMP backing for ATTR polyneuropathy drug | ||
| 22.10. | Seaport docks $225m for its improved neuropsychiatry drugs | ||
| 21.10. | Novo Nordisk closes on EU okay for haemophilia antibody | ||
| 21.10. | Gilead, MSD say HIV combo could be weekly, oral HIV drug | ||
| 21.10. | Roche trial confirms Vabysmo efficacy in minorities | ||
| 21.10. | PursueCare brings Pear addiction DTx apps back to life | ||
| 21.10. | FDA clears Astellas' Vyloy as first claudin 18.2 cancer drug | ||
| 18.10. | AbbVie gets continuous Parkinson's drug over the line in US | ||
| 18.10. | MSD preparing to take on Beyfortus with RSV antibody | ||
| 18.10. | BenevolentAI CEO steps down as founders make a comeback | ||
| 18.10. | Sanofi invests €300m in Orano Med's lead-based radioligands | ||
| 18.10. | Sage cuts a third of its workforce after R&D setbacks | ||
| 17.10. | NICE backs first targeted therapy for ALK+ lung cancer | ||
| 17.10. | Australia joins EU in turning down Alzheimer's drug Leqembi | ||
| 17.10. | First human skin atlas points way to healing without scars | ||
| 17.10. | NIH study backs Bavarian Nordic mpox jab for adolescents | ||
| 17.10. | Wave surges on first RNA editing data in humans | ||
| 16.10. | Head and neck cancer trials 'becoming less diverse' |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
